BioAge Labs, Inc. Common Stock (BIOA) Stock
NASDAQ · BIOA
7.13
Fundamentals
Market cap
$323.57M
Price / Earnings ratio
-3.5x
Price / Sales ratio
32.0x
Price / Book ratio
0.9x
Return on assets
-27.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
NeutralBIOAAugust 6, 2026
Zacks Investment ResearchNeutral
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BIOA

Stocktwits
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
NeutralBIOAJuly 31, 2026
StocktwitsNeutral
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA

MarketBeat
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
NeutralBIOAJune 6, 2026
MarketBeatNeutral
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BIOA

MarketBeat
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
NeutralBIOAMay 8, 2026
MarketBeatNeutral
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BIOA
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy3
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
11M7M4M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
354M234M117M0
Revenue to Profit
2025$9.0M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-80.6M
Net incomeEarnings
No data available
% positive news of 8 articles
published over the past 14 days
Latest news

Zacks Investment Research
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
NeutralBIOAAugust 6, 2026
Zacks Investment ResearchNeutral
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BIOA

Stocktwits
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
NeutralBIOAJuly 31, 2026
StocktwitsNeutral
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA

MarketBeat
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
NeutralBIOAJune 6, 2026
MarketBeatNeutral
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease
BIOA

MarketBeat
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
NeutralBIOAMay 8, 2026
MarketBeatNeutral
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials
BIOA

Zacks Investment Research
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
NeutralBIOAApril 21, 2026
Zacks Investment ResearchNeutral
Wall Street Analysts Predict an 183.67% Upside in BioAge Labs, Inc. (BIOA): Here's What You Should Know
BIOA

Investors Business Daily
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
NeutralBIOAJanuary 12, 2026
Investors Business DailyNeutral
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BIOA

The Motley Fool
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
NeutralBIOAOctober 7, 2024
The Motley FoolNeutral
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
BIOA

24/7 Wall Street
An Airline, Biotechs, and More See Huge Insider Buying
NeutralBIOAOctober 6, 2024
24/7 Wall StreetNeutral
An Airline, Biotechs, and More See Huge Insider Buying
BIOA
About BioAge Labs, Inc. Common Stock
No description available.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees60
CEODr. Kristen Fortney Ph.D.
IPO DateMay 10, 2013
HeadquartersEmeryVille, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Kristen Fortney Ph.D. | Co-Founder, CEO, President, Treasurer, Secretary & Director | 1984 |
| Dr. Eric Morgen M.D. | Co-Founder, COO & Director | 1983 |
| Dr. Paul D. Rubin M.D. | Chief Medical Officer & Executive VP of Research | 1954 |
| Dr. Dov A. Goldstein M.B.A., M.D. | Chief Financial Officer | 1967 |
| Mr. Shane Barton CPA | Senior Vice President of Finance & Accounting | 1971 |
| Mr. Rusty Montgomery Ph.D. | Senior Vice President of Research | — |
| Ms. Julie Gammelgard | Senior Vice President of People | — |
| Dr. Peng Leong M.B.A., Ph.D. | Chief Business Officer & Therapeutic Area Head of Brain Aging | — |
| Mr. BJ Sullivan Ph.D. | Chief Strategy Officer | — |
| Ms. Ann C. Neale RN BSN | Chief Development Officer | — |
Fundamentals
Valuation
Market cap$323.57M
Price-to-sales ratio31.96
Price-to-book value0.88
Price-earnings ratio-3.50
Return on Equity-29.00%
Return on Sales-867.00%
Return on Assets-27.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-2.38
Income Statement
Average volume669,588
EBITDA$-89.07M
1 year high (52w)$25.96
1 year low (52w)$5.04
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsBuy5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
3 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$33.33
Est return
375.51%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | +13.6 | +16.5 | -14.2 | -66.8 | ||||||||
| 2025 | -17.4 | -1.7 | -13.0 | +17.3 | -4.3 | +2.0 | +6.5 | +19.7 | +26.5 | +27.9 | +27.9 | +48.2 |
| 2026 | +48.0 | +10.8 | -19.4 | -5.0 | +3.0 | +42.5 | -62.7 | -11.9 | -25.9 |



